Discounted Cash Flow (DCF) Analysis Levered
Bionano Genomics, Inc. (BNGO)
$1.14
+0.06 (+5.56%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.33 | -0.06 | 4.66 | -0.82 | -2.41 | 2.84 | 3.79 | 5.06 | 6.76 | 9.03 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -20.28 | -29.59 | -33.66 | -72.75 | -127.22 | -127.72 | -170.64 | -227.99 | -304.62 | -406.99 |
Weighted Average Cost Of Capital
Share price | $ 1.14 |
---|---|
Beta | 2.317 |
Diluted Shares Outstanding | 289.21 |
Cost of Debt | |
Tax Rate | -1.44 |
After-tax Cost of Debt | 2.55% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 14.540 |
Total Debt | 11.67 |
Total Equity | 329.70 |
Total Capital | 341.37 |
Debt Weighting | 3.42 |
Equity Weighting | 96.58 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
Capital Expenditure | -0.33 | -0.06 | 4.66 | -0.82 | -2.41 | 2.84 | 3.79 | 5.06 | 6.76 | 9.03 |
Free Cash Flow | -20.28 | -29.59 | -33.66 | -72.75 | -127.22 | -127.72 | -170.64 | -227.99 | -304.62 | -406.99 |
WACC | ||||||||||
PV LFCF | -111.90 | -131 | -153.36 | -179.54 | -210.18 | |||||
SUM PV LFCF | -785.98 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 14.13 |
Free cash flow (t + 1) | -415.13 |
Terminal Value | -3,422.37 |
Present Value of Terminal Value | -1,767.37 |
Intrinsic Value
Enterprise Value | -2,553.35 |
---|---|
Net Debt | 6.58 |
Equity Value | -2,559.93 |
Shares Outstanding | 289.21 |
Equity Value Per Share | -8.85 |